BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36574405)

  • 21. Targeting the proteostasis network in Huntington's disease.
    Soares TR; Reis SD; Pinho BR; Duchen MR; Oliveira JMA
    Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
    Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
    Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
    Morozko EL; Ochaba J; Hernandez SJ; Lau A; Sanchez I; Orellana I; Kopan L; Crapser J; Duong JH; Overman J; Yeung S; Steffan JS; Reidling J; Thompson LM
    J Huntingtons Dis; 2018; 7(4):321-335. PubMed ID: 30452420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
    Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
    J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
    Ban JJ; Chung JY; Lee M; Im W; Kim M
    Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
    Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
    Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serine 421 regulates mutant huntingtin toxicity and clearance in mice.
    Kratter IH; Zahed H; Lau A; Tsvetkov AS; Daub AC; Weiberth KF; Gu X; Saudou F; Humbert S; Yang XW; Osmand A; Steffan JS; Masliah E; Finkbeiner S
    J Clin Invest; 2016 Sep; 126(9):3585-97. PubMed ID: 27525439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.
    Díaz-Hernández M; Valera AG; Morán MA; Gómez-Ramos P; Alvarez-Castelao B; Castaño JG; Hernández F; Lucas JJ
    J Neurochem; 2006 Sep; 98(5):1585-96. PubMed ID: 16787406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
    Luo H; Cao L; Liang X; Du A; Peng T; Li H
    Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1α.
    Hyrskyluoto A; Bruelle C; Lundh SH; Do HT; Kivinen J; Rappou E; Reijonen S; Waltimo T; Petersén Å; Lindholm D; Korhonen L
    Hum Mol Genet; 2014 Nov; 23(22):5928-39. PubMed ID: 24951540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
    Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
    Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
    Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
    J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.
    Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A
    Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.
    Lee YH; Tsai YS; Chang CC; Ho CC; Shih HM; Chen HM; Lai HL; Lee CW; Lee YC; Liao YC; Yang UC; Cheng TH; Chern Y; Soong BW
    Mov Disord; 2022 Apr; 37(4):767-777. PubMed ID: 34951052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
    Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
    Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.